Storia in 2 fonti

CX Daily: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad

Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing a rethink

Raccontata da

scmp.com

caixinglobal.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

caixinglobal.comStai leggendo1 g fa

CX Daily: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad

Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing a rethink

originale

scmp.com2 g fa

China AI drug-design deals swell as US scrutiny mounts

Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.

Leggi questa versione → originale

Timeline cronologica

giovedì 2 luglio 2026·scmp.com
China AI drug-design deals swell as US scrutiny mounts
Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.
venerdì 3 luglio 2026·caixinglobal.com
CX Daily: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing a rethink